Advertisement

Topics

CellSight, Boehringer form Alliance for Anti-tumor T-Cell Activation Technology

08:18 EST 8 Nov 2017 | Contract Pharma

The new technology could help to accelerate the development of critical immuno-oncological therapies

Original Article: CellSight, Boehringer form Alliance for Anti-tumor T-Cell Activation Technology

NEXT ARTICLE

More From BioPortfolio on "CellSight, Boehringer form Alliance for Anti-tumor T-Cell Activation Technology"

Advertisement
Quick Search
Advertisement
Advertisement